Novartis Aktie

Novartis für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 904278 / ISIN: CH0012005267

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
08.07.2025 07:14:46

Press Release: Novartis receives approval for -2-

References

1. Eight African countries participated in Swissmedic's Marketing

Authorization for Global Health Products (MAGHP) procedure

https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html

for Coartem Baby -- Burkina Faso, Cote d'Ivoire, Kenya, Malawi,

Mozambique, Nigeria, Tanzania and Uganda -- and are expected to approve

the medicine following approval by Swissmedic. These eight countries

account for 47% of estimated cases in 2023, according to the WHO's Global

Health Observatory

https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-number-of-malaria-deaths

2. WHO. Malaria vaccines (RTS,S and R21)

https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine#::text=Malaria%20vaccines%20should%20be%20provided%20to%20children%20in%20a%20schedule,

age%20based%20on%20operational%20considerations.

3. Reddy, Valentina et al. Global estimates of the number of pregnancies at

risk of malaria from 2007 to 2020: a demographic study. The Lancet Global

Health, Volume 11, Issue 1, e40 - e47

4. Ceesay SJ et al. Malaria Prevalence among Young Infants in Different

Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21.

doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.

5. D'Alessandro U, et al. Malaria in infants aged less than six months - is

it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi:

10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.

6. Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first

year of life. Parasitology. 2016;143(2):129-138.

doi:10.1017/S0031182015001626

7. WHO. Malaria. https://www.who.int/news-room/fact-sheets/detail/malaria

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

July 08, 2025 01:15 ET (05:15 GMT)

Analysen zu Novartis AGmehr Analysen

10.10.25 Novartis Neutral UBS AG
06.10.25 Novartis Buy Deutsche Bank AG
24.09.25 Novartis Neutral UBS AG
22.09.25 Novartis Neutral UBS AG
17.09.25 Novartis Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG (Spons. ADRS) 113,50 0,00% Novartis AG (Spons. ADRS)
Novartis AG 114,25 -0,17% Novartis AG